Stillwater Capital Advisors LLC Grows Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Stillwater Capital Advisors LLC lifted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.5% during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 22,535 shares of the medical research company’s stock after buying an additional 118 shares during the quarter. Thermo Fisher Scientific makes up 2.1% of Stillwater Capital Advisors LLC’s holdings, making the stock its 21st largest holding. Stillwater Capital Advisors LLC’s holdings in Thermo Fisher Scientific were worth $11,758,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. Silicon Valley Capital Partners bought a new stake in Thermo Fisher Scientific in the 1st quarter valued at $29,000. OLD Mission Capital LLC bought a new stake in Thermo Fisher Scientific in the 4th quarter valued at $31,000. Live Oak Investment Partners bought a new stake in Thermo Fisher Scientific in the 4th quarter valued at $36,000. Grey Fox Wealth Advisors LLC bought a new stake in Thermo Fisher Scientific in the 4th quarter valued at $43,000. Finally, Barrett & Company Inc. bought a new stake in Thermo Fisher Scientific in the 1st quarter valued at $43,000. Hedge funds and other institutional investors own 87.06% of the company’s stock.

Wall Street Analyst Weigh In

TMO has been the topic of a number of research reports. KeyCorp reduced their price target on shares of Thermo Fisher Scientific from $710.00 to $640.00 in a report on Thursday, May 25th. Citigroup began coverage on shares of Thermo Fisher Scientific in a report on Wednesday, September 6th. They issued a “buy” rating and a $625.00 target price on the stock. Wells Fargo & Company boosted their target price on shares of Thermo Fisher Scientific from $505.00 to $520.00 and gave the stock an “underweight” rating in a report on Friday, July 28th. StockNews.com upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Friday. Finally, Robert W. Baird reduced their target price on shares of Thermo Fisher Scientific from $664.00 to $625.00 and set an “outperform” rating on the stock in a report on Thursday, July 27th. One research analyst has rated the stock with a sell rating, one has given a hold rating and twelve have given a buy rating to the company. According to MarketBeat.com, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and an average price target of $631.71.

Insider Activity

In other news, EVP Gianluca Pettiti sold 3,000 shares of the stock in a transaction that occurred on Wednesday, August 30th. The shares were sold at an average price of $557.77, for a total transaction of $1,673,310.00. Following the transaction, the executive vice president now directly owns 17,556 shares in the company, valued at $9,792,210.12. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Thermo Fisher Scientific news, CFO Stephen Williamson sold 14,100 shares of the firm’s stock in a transaction that occurred on Tuesday, August 1st. The shares were sold at an average price of $550.00, for a total value of $7,755,000.00. Following the completion of the sale, the chief financial officer now directly owns 27,393 shares in the company, valued at $15,066,150. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Gianluca Pettiti sold 3,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 30th. The shares were sold at an average price of $557.77, for a total transaction of $1,673,310.00. Following the completion of the sale, the executive vice president now owns 17,556 shares of the company’s stock, valued at $9,792,210.12. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 28,700 shares of company stock worth $15,799,270. Corporate insiders own 0.32% of the company’s stock.

Thermo Fisher Scientific Price Performance

Thermo Fisher Scientific stock opened at $506.86 on Tuesday. The stock has a market cap of $195.62 billion, a price-to-earnings ratio of 34.72, a price-to-earnings-growth ratio of 2.43 and a beta of 0.77. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.42 and a quick ratio of 1.02. Thermo Fisher Scientific Inc. has a 1 year low of $475.77 and a 1 year high of $609.85. The firm has a 50-day moving average of $540.37 and a two-hundred day moving average of $541.53.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, July 26th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.43 by ($0.28). Thermo Fisher Scientific had a net margin of 13.14% and a return on equity of 18.59%. The company had revenue of $10.69 billion during the quarter, compared to analysts’ expectations of $10.99 billion. During the same period last year, the firm earned $5.51 earnings per share. Thermo Fisher Scientific’s quarterly revenue was down 2.6% on a year-over-year basis. On average, research analysts forecast that Thermo Fisher Scientific Inc. will post 22.37 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 13th. Stockholders of record on Friday, September 15th will be paid a dividend of $0.35 per share. The ex-dividend date is Thursday, September 14th. This represents a $1.40 dividend on an annualized basis and a dividend yield of 0.28%. Thermo Fisher Scientific’s dividend payout ratio is presently 9.57%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the United States and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, clinical next-generation sequencing, bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.